Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Amortization (2015 - 2019)

AC Immune (ACIU) reported Amortization of $109614.7 for Q3 2019, down 96.72% on a QoQ basis from $3.3 million in Q4 2018.

AC Immune (ACIU) has 5 years of Amortization data on file, last reported at $109614.7 in Q3 2019.

  • Quarterly Amortization changed N/A year-over-year to $109614.7 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $5.9 billion (changed N/A YoY) and the FY2021 annual result came in at $5.6 million, up 18.9% from the prior year.
  • Amortization fell to $109614.7 in Q3 2019 per ACIU's latest filing, from $3.3 million in the prior quarter.
  • Across five years, Amortization topped out at $3.5 billion in Q2 2018 and bottomed at $109614.7 in Q3 2019.
  • The 5-year median for Amortization is $3.3 million (2016), against an average of $985.7 million.
  • The widest annual swing landed in 2017, when Amortization soared 72743.42%; it then tumbled 99.86% in 2018.
  • Tracing ACIU's Amortization over 5 years: stood at $2.4 million in 2015, then soared by 36.36% to $3.3 million in 2016, then soared by 72743.42% to $2.4 billion in 2017, then plunged by 99.86% to $3.3 million in 2018, then slumped by 96.72% to $109614.7 in 2019.
  • Per Business Quant, the three latest ACIU Amortization figures stand at $109614.7 (Q3 2019), $3.3 million (Q4 2018), and $3.5 billion (Q2 2018).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -13.75 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 AC Immune 325.88 Mn 211.53 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 109,614.75
Sep 30, 2019 109,614.75
Dec 31, 2018 3.34 Mn
Dec 31, 2018 3.34 Mn
Jun 30, 2018 3.52 Bn
Jun 30, 2018 3.52 Bn
Dec 31, 2017 2.38 Bn
Dec 31, 2017 2.38 Bn
Dec 31, 2016 3.27 Mn
Dec 31, 2016 3.27 Mn
Dec 31, 2015 2.40 Mn
Dec 31, 2015 2.40 Mn